Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Savolitinib Alone and with Itraconazole in Healthy Subjects
NCT04121910Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Savolitinib AUC Ratio (Combination vs Alone) and Savolitinib Cmax Ratio (Combination vs Alone). Started Nov 2019; status: completed.
02
Drugs
savolitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04121910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121910.